MSB
vs
S
S&P/ASX 300
MSB
Over the past 12 months, MSB has underperformed S&P/ASX 300, delivering a return of -4% compared to S&P/ASX 300's +1% growth.
Stocks Performance
MSB vs S&P/ASX 300
Performance Gap
MSB vs S&P/ASX 300
Performance By Year
MSB vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mesoblast Ltd
Glance View
Mesoblast is a biotechnology company that develops cell-based medicines, especially treatments made from donated adult stem cells. Its main work is to research, test, and seek approval for therapies aimed at hard-to-treat inflammatory and immune-related diseases, as well as some serious spine and heart conditions. The company does not sell a broad range of consumer products. It makes money when its drug candidates are licensed, approved, or commercialized through partners, and potentially through product sales and royalty streams tied to those therapies. Its customers are mainly hospitals, doctors, and larger pharmaceutical partners rather than end consumers. What makes Mesoblast different is that it sits in the cell-therapy part of drug development, where the product is living cells rather than a standard pill or injection. That makes the science, manufacturing, and regulatory path more complex than for many drugmakers, but it also gives the company a focused role as a specialist developer of regenerative medicines.
